Research news

UCLH has welcomed the news that the Oxford-AstraZeneca coronavirus vaccine – which UCLH played a significant role in trialling – has today been approved for use in the UK.

UCLH has opened a new vaccine research centre with two clinical trials testing a long-acting antibody combination treatment to protect against Covid-19.

A large international trial involving UCL and UCLH has found that pembrolizumab, a form of immunotherapy, more than doubled the ‘progression free survival’ time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its ‘Phase 3’ trials which involved UCLH that show its candidate vaccine is effective at preventing COVID-19 and offers a high level of protection.

Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research involving UCLH.